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A stable HMG-CoA reductase (HMGR) reaction in vitrowas developed by a sensitive, selective and precise
liquid chromatography–tandem mass spectrometry (LC–MS/MS) method. The optimized enzyme reac-
tion condition contained 1.5 μg of HMGR, 20 nM of NADPH with 50 min of reaction time. The method
was validated by several intra- and inter-day assays. The production transitions ofm/z 147.0/59.1 and m/z
154.0/59.1 were used to detect and quantify mevalonolactone (MVAL) and MVAL-D7, respectively. The
accuracy and precision of the method were evaluated over the concentration range of 0.005–
1.000 μg/mL for MVAL and 0.010–0.500 μg/mL for lovastatin acid in three validation batch runs. The
lower limit of quantitation was found to be 0.005 μg/mL for MVAL and 0.010 μg/mL for lovastatin acid.
Intra-day and inter-day precision ranged from 0.95% to 2.39% and 2.26% to 3.38% for MVAL, 1.46% to 3.89%
and 0.57% to 5.10% for lovastatin acid, respectively. The results showed that the active ingredients in
Xuezhikang capsules were 12.2 and 14.5 mg/g, respectively. This assay method could be successfully
applied to the quality control study of Xuezhikang capsule for the ﬁrst time.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As a major membrane lipid, cholesterol has numerous biolo-
gical functions. Many human diseases such as cardiovascular dis-
eases are correlated with enzyme defects, which may lead to the
abnormal regulation of cholesterol biosynthesis and the accumu-
lation of its intermediate products [1–3]. Mevalonate (MVA)
pathway, a cholesterol biosynthetic pathway, is proceeded in the
endoplasmic reticulum [4]. HMGR is responsible for catalyzation of
HMG-CoA to CoA and MVA by four-electron reductive deacylation
[5]. MVA equilibrates with MVAL under natural pH conditions.
HMGR plays a key role in the regulation of sterol biosynthesis and
cholesterol production, which makes it an attractive target in the
in-depth development of hypolipidemic drugs.
Analytical methods for assay of HMGR activity, including
radioisotope (RI) technique, high performance liquid chromato-
graphy (HPLC), and chromatography coupled mass spectrometry,
have been reported. The primary RI method measures theon and hosting by Elsevier B.V. All
University.
tai University, Yantai 264005,
.radioactivity in [14C]mevalonic acid (MVA) or 5-[32P] phospho-
MVA produced from labeled HMG-CoA, which is simple but re-
quires the handling of radiolabeled materials [6–9]. Although HPLC
method [10] and gas chromatography mass spectrometry (GC–MS)
[11–13] are used to overcome disadvantages of RI method, these
methods also have cumbersome natures such as low sensitivity for
HPLC, complicated sample derivatization steps and a long analy-
tical process to eliminate interfering peaks for GC–MS [14–16].
Liquid chromatography–tandem mass spectrometry (LC–MS/MS)
has been used more readily than GC–MS to analyze relatively polar
compounds due to its high speciﬁcity, accuracy and multiplexing
options [17–20], even for small molecular weight compounds like
MVA or MVAL, scanning in multiple reaction monitoring (MRM)
for speciﬁc mass transitions [21–23].
Xuezhikang, extracted from red yeast rice, is a Chinese tradi-
tional medicine which is widely used in the treatment of cardio-
vascular diseases. Previous clinical studies show that it also has
anti-inﬂammatory effects [24], and can improve endothelial
function [25]. The hypolipidemic mechanism of Xuezhikang is ef-
ﬁcient inhibition of HMGR by natural lovastatin which is the major
component of it. Besides, Xuezhikang also contains the homologs
of lovastatin, unsaturated fatty acids, ﬂavonoids, plant sterols and
other bioactive substances [26]. Although active ingredients of
Xuezhikang are very important for clinical studies, currently, thererights reserved. This is an open access article under the CC BY-NC-ND license
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Xuezhikang production. Quantiﬁcation of Xuezhikang requires a
speciﬁc and sensitive method which is suitable for the routine
analysis of biological samples. Some quantiﬁed components of
Xuezhikang rather than the quantiﬁcation methods applied have
been reported in the literature. The methods used include HPLC
for Xuezhikang [27,28], as well as micellar electrokinetic capillary
chromatography [29], nuclear magnetic resonance (NMR) evalua-
tion [30], and chromatography coupled mass spectrometry tech-
nology to detect several components such as monacolins, pig-
ments and citrinin in red yeast rice [31–34]. However, no method
was reported for quantiﬁcation of total active ingredients of
Xuezhikang by inhibition of HMG-CoA reductase in vitro with
HPLC-tandem mass spectrometry (MS/MS).
With MVAL-D7 as the internal standard, we studied a high-
throughput and sensitive enzyme method to quantify the active
ingredients of Xuezhikang. The validated method and enzyme
reaction system in vitro were used for the ﬁrst time to analyze the
active ingredients of Xuezhikang, and can be developed for the
quality control of Xuezhikang to ensure its clinical efﬁcacy.2. Materials and methods
2.1. Chemicals and reagents
HMG-CoA, HMGR, NADPH, MVAL, DL-dithiothreitol, formic acid
(purity496%), ammonium formate and ammonium hydroxide (28%
NH3 in H2O, purity499.99%) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). The internal standard used in the assay method
was DL-mevalonolactone-4,4,5,5,6,6,6,-D7 (purity499%) from CDN
Isotopes (Pointe-Claire, Quebec, Canada). Lovastatin acid (96%) was
purchased from Toronto Research Chemicals (North York, Canada).
Xuezhikang capsules were obtained from Peking University WBL
Biotech Co., Ltd. (Beijing, China). HPLC-grade methanol and acetoni-
trile were purchased from MERCK (Darmstadt, Germany). ISOLUTE
ENVþ (3 mL/100 mg) was purchased from Biotage, Inc. (Uppsala,
Sweden). De-ionized water was further puriﬁed by a Milli-Q water
purifying system (Millipore Corporation, Bedford, MA, USA).
2.2. Instrumentations and conditions
The system consists of an API 4000 mass spectrometer (Applied
Biosystems Sciex, Ontario, Canada) with an electrospray ionization
(ESI) probe and an Agilent RRLC series HPLC system (Agilent
Technologies, Palo Alto, CA, USA). Chromatography was performed
on a ZORBAX SB-C18 (150 mm4.6 mm, 5 μm) at the room tem-
perature using an isocratic elution with ammonium formate
(10 mM, pH 8.0) – acetonitrile (70:30, v/v). The sample injection
volume was 30 μL and the cycle time was 5 min per injection at a
ﬂow rate of 0.8 mL/min with split. The retention time of the ana-
lyte and the internal standard was 1.46 min.
Multiple reaction monitoring (MRM) at unit resolution was
employed to monitor the transitions of the protonated forms of
MVAL at m/z 147.0-59.1 and MVAL-D7 at m/z 154.0-59.1 in the
negative ion mode. Optimized MS conditions were described as
follows: curtain gas, gas 1 and gas 2 (all nitrogen) with 20, 45 and
45 units, respectively; dwell time with 100 ms; ion spray voltage
with 4500 V; source temperature with 500 °C; declustering
potentials with 40 eV; collision energies with 18 eV.
2.3. Preparation of stock and working solutions, standards and
quality control samples
The stock solutions of MVAL and lovastatin acid were prepared
according to dissolving reference standards. These stock solutionswere then used to prepare the working solutions of MVAL and lo-
vastatin acid in acetonitrile: a mixture of 10 mM of ammonium for-
mate and HPLC grade acetonitrile (70:30, v/v) by appropriate dilu-
tion. Calibration curve standards consisting of eight concentration
levels were prepared in a concentration range of 0.005–1.000 μg/mL
for MVAL and 0.010–0.500 μg/mL for lovastatin acid. Similarly,
quality control (QC) standards were prepared for the lower limit of
quantiﬁcation (LLOQ QC), low quality control (LQC), medium quality
control (MQC) and high quality control (HQC) for the analytes within
the calibration curve range. The calibration curve standards and QC
samples were stored at 2–8 °C for method validation. All the stock
solutions were stored at 35 °C for further use.
2.4. Preparation of Xuezhikang samples
Six capsules of Xuezhikang were taken from two batches, re-
spectively, and the capsule contents of each batch were mixed and
milled. The content (0.3 g) was accurately weighed, and dissolved
with 75% ethanol for ultrasound treatment about 10 min. The su-
pernatant was obtained by centrifuging at 2000 r/min for 5 min.
The transformed Xuezhikang solutions were diluted to 25.0 and
75.0 ng/mL after adding 0.5 M of potassium hydroxide solution,
which transformed lovastatin into lovastatin acid in Xuezhikang as
sample solutions.
2.5. HMG-CoA reductase reaction in vitro
The preparation of enzyme activity assay was conducted ac-
cording to the study [7] with some modiﬁcations using HMG-CoA
reductase (073M4047V 4.70 U/mL) prepared by diluting 10 μL of
puriﬁed human HMG-CoA reductase to a ﬁnal volume of 1.6 mL
with enzyme reaction buffer. The HMG-CoA (0.025 μM) was di-
luted with enzyme reaction buffer which contains potassium
phosphate buffer (100 mM, pH 7.4), EDTA (0.1 mM), DTT (5 mM),
and NADPH (0.016 μM), achieving a ﬁnal reaction volume of
140 mL. Samples were incubated for 50 min at 37 °C, whereupon
the reaction was terminated by the addition of HCl (20 mL, 5 M) for
15 min at 37 °C. A sample (2.14 mL) containing water (1 mL), HCl
(0.9 mL, 0.1 M), MVAL-D7 (100 mL) and reaction solutions (140 mL)
was added to each tube in order. The solutions were vortexed for
20 s and stored at room temperature for at least 10 min to ensure
the lactonization of biosynthetic MVA.
2.6. Extraction procedure
For the extraction of MVAL and IS (MVAL-D7), we employed the
solid-phase extraction (SPE), in which solid-phase extraction car-
tridges (3 mL/100 mg) were conditioned with 1 mL of water, 2 mL of
methanol–water (50:50, v/v) and 3 mL of methanol. Methanol was
washed by 1 mL of 0.1 M HCl, and the samples (see sample pre-
paration) were loaded onto the solid phase carriers under low va-
cuum condition. Then cartridges were washed by 1 mL of 0.1 M HCl
and 1 mL of water, and dried naturally. Cartridges were eluted with
0.5 mL of methanol for 5 times. The combined elutes were evapo-
rated to dryness at 40 °C in nitrogen evaporator, and the dry residues
were reconstituted in 200 mL of 0.2% ammonium hydroxide, followed
by a mixture of 10 mM of ammonium formate and HPLC grade
acetonitrile (70:30, v/v) in a vortex mixer for 20 s. The reconstituted
samples were transferred into auto-sampler vials, and 30 mL of
sample was injected into the LC–MS/MS system for analysis.
2.7. Method validation for MVAL and reaction system
The full method validation was performed according to the
guideline for the validation of bio-analytical methods set by the
Food and Drug Administration (FDA) [35]. The validation was
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linearity, precision, accuracy, matrix effect, extraction recovery,
and stability.
Speciﬁcity was evaluated by the analysis of enzyme reaction
system in six different HMG-CoA reductase sources. Three preci-
sion and accuracy batches of calibration curve standard at eight
different concentration levels ranging from 0.005 to 1.000 μg/mL
for spiked MVAL and 0.010 to 0.500 μg/mL for lovastatin acid were
prepared and analyzed. Weighted (w¼1/x2) linear regression was
used to construct the calibration curves of spiked MVAL and lo-
vastatin acid. The accuracy and precision of intra- and inter-batch
assay was evaluated by analyzing six replicates of QC samples at
four concentration levels (0.005, 0.010, 0.080, and 0.800 μg/mL for
MVAL, and 0.010, 0.025, 0.050, and 0.100 μg/mL for lovastatin acid)
through three different analytical batches. Recovery of MVAL was
evaluated by comparing the peak areas response of the extracted
samples with that of the unextracted stock solutions at the three
QC concentration levels of 0.010, 0.080 and 0.800 μg/mL of MVAL.
Matrix effect of MVAL was analyzed by six replicates of QC sam-
ples. The matrix factor (MF) of each analyte or IS was obtained by
calculating peak area ratio of post-extracted spiked samples with
peak area of neat solutions. Extraction recovery was determined
by comparing peak areas of extracted QC samples with those of
the post-extracted spiked samples at corresponding concentra-
tions. The stability of MVAL was performed at three QC levels, each
with six replications. The stability results were evaluated with the
freshly spiked calibration curve (CC) and QC samples, and the
percentage concentration deviation was calculated.
2.8. Method application
20 μL of each concentration of Xuezhikang samples and lo-
vastatin acid working solutions were respectively added into the
optimized HMG-CoA reductase reaction system to inhibit HMGR,
which led to the reduction of MVAL compared with the amount of
that when no inhibitor was added into the HMGR reaction (ne-
gative control). The inhibition rate to HMGR was calculated as
follows:
Inhibition rate %
Conc. of MVAL in negative control Conc. of MVAL in sample
Conc. of MVAL in negative control
100%
( )
= − ×
The amount of lovastatin acid and other HMGR inhibitors in
Xuezhikang samples was calculated as lovastatin acid equivalents
obtained from a calibration curve constructed from the plot of
inhibition rate of HMGR versus the concentration of lovastatin
acid. Concentrations were calculated using logistic dose response
in pharmacology/chemistry in software Origin 8.0:
y A A A / 1 X/X2 1 2 0 P= + ( − ) [ + ( ) ]
where y is the inhibition rate to HMGR, X is the concentration
of lovastatin acid (ng/mL), A1, A2, X0 and P are parameters origi-
nated from software. Concentration of HMGR inhibitors in Xuez-
hikang was calculated by inhibition rate of Xuezhikang in the
formula.3. Results and discussion
3.1. Optimization of enzyme reaction
Enzyme reaction was observed under some test conditions. The
results revealed that 1.5 μg of HMGR, 20 nM of NADPH and 50 min
of reaction time were the optimized enzyme reaction conditions.
Enzyme reaction was quickly performed on ice to avoid HMGRprotein degradation. Factors such as the amount of enzyme and
NADPH, pre-incubation time and incubation time could affect the
enzyme reaction, which was expressed as the transformation ef-
ﬁciency of substrate in spiked samples against a calibration curve.
Therefore, we studied the enzyme reaction under different con-
ditions in order to obtain the optimized reaction conditions.
Various amount of HMG-CoA reductase (0.25, 0.50, 0.75, 1.00,
1.50, 1.75, and 2.00 μg) were respectively added into the inactivated
reaction mixture composed of sodium phosphate buffer (200 mM,
pH 7.4) and DL-dithiothreitol (DTT) (10 mM). NADPH with a rela-
tively higher concentration may reduce the test sensitivity, as the
nicotinamide adenine dinucleotide in NADPH exerts a great effect on
ion suppression [36]. Therefore, NADPH with different concentra-
tions (2.5, 5.0, 7.5, 10.0, 12.5, 15.0, 17.5, and 20.0 nM) was tested in the
enzyme assay so as to choose an appropriate amount which has no
impact on enzyme activity measurement but meets the need of the
substrate. As the pre-incubation time determines the binding capa-
city between inhibitor and enzyme, HMGR was pre-incubated for
several intervals of 5, 10, 15, 20, 25, and 30 min at 37 °C. According to
the enzyme activity, 2.5 nM of HMG-CoA was added in the reaction
system to trigger the reaction. The previous studies show that the
amount of reaction product is closely related to the amount of en-
zyme [37]. The complete reaction mixture (with a ﬁnal volume of
140 mL) was incubated at 37 °C and stopped at ﬁxed intervals (15, 30,
45, 60, 75 and 90 min) by 20 mL of 5 M HCl. With the lactonization of
the reaction with HCl, 0.1 M HCl was added to promote the pro-
duction of MVAL.
Fig. 1 shows, according to the signiﬁcant variation of transfor-
mation efﬁciency, the amount of HMGR and NADPH, and the re-
action time exert greater impacts on HMG-CoA reductase reaction.
However, pre-incubation time has little effect on enzyme reaction.
3.2. Method validation
3.2.1. Selectivity and linearity
Interfering peaks were not observed at the retention time of
MVAL and MVAL-D7. The blank sample (without IS and MVAL),
MVAL standard solution (0.010 mg/mL) and sample generated from
the enzyme reaction were injected under the established LC–MS/
MS conditions, respectively. Their representative chromatograms
are shown in Fig. 2.
The calibration curve of MVAL and the inhibition rate curve of
Lovastatin acid were both reliably reproducible over the standard
concentrations. Good correlation was obtained within a range of
0.005–1.000 μg/mL for MVAL (r¼0.9968) and 0.010 – 0.500 μg/mL
for lovastatin acid (r¼0.9980).
3.2.2. Precision and accuracy
The results of precision and accuracy are shown in Table 1. The
intra-day precision (RSD) was less than 2.39% and 3.89% for MVAL
and lovastatin acid at each QC level, respectively, and the inter-day
precision (RSD) was less than 3.38% and 5.10%. The accuracy (RE)
was within 101.63% of the target values. The above values were
within the acceptable range and indicated that the developed
method and reaction system were accurate and precise.
3.2.3. Matrix effect
The matrix effect was minimal based on peak areas ratios of
MVAL and MVAL-D7 in post-extraction samples (low, medium and
high QC) with peak area of the corresponding neat solutions. Ta-
ble 2 shows that these ratios at three QC concentration levels were
83.83%, 87.83% and 93.68% with RSD of 1.92%, 5.65% and 1.88%,
respectively; and the mean ratio of MVAL-D7 was 87.02% with a
RSD of 4.02%. The percentage coefﬁcient of variance of both the
analytes and internal standard was within the acceptance.
Fig. 1. Relation of HMG CoA reductase activity (substrate transformation) and the amount of HMG-CoA reductase (A), NADPH (B), pre-incubation time (C) and reaction time (D).
Fig. 2. Representative MRM chromatograms of MVAL in enzyme reaction matrix. (A) blank matrix; (B) blank matrix spiked with 0.010 μg/mL of MVAL (left) and MVAL-D7
(right); (C) real matrix sample generated by enzyme reaction (left) and MVAL-D7 (right).
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Table 1
Intra-day and inter-day accuracy and precision of the method for MVAL and lo-
vastatin acid.
Analytes Nominal concentration
(mg/mL)
Intra-day varia-
tion (n¼6)
Inter-day varia-
tion (n¼18)
Nominal
(%)
RSD
(%)
Nominal
(%)
RSD
(%)
MVAL 0.005 98.26 1.91 98.26 2.53
0.010 99.18 2.39 99.18 3.38
0.080 101.26 1.96 101.26 3.03
0.800 99.28 0.95 99.28 2.26
Lovastatin acid 0.010 102.08 3.19 102.08 3.31
0.025 100.08 1.46 100.08 0.91
0.050 100.12 3.04 100.12 0.57
0.100 101.63 3.89 101.63 5.10
Table 2
Matrix effect evaluation for MVAL and MVAL-D7.
Analytes Nominal concentration
(μg/mL)
Mean (%) SD (%) RSD (%)
MVAL 0.01 83.83 1.61 1.92
0.08 87.83 3.83 5.65
0.80 93.68 1.20 1.88
MVAL-D7 0.75 87.02 2.70 4.02
Table 3
Extraction recovery evaluation for MVAL and MVAL-D7.
Analytes Nominal concentration (μg/mL) Mean (%) SD (%) RSD (%)
MVAL 0.01 93.37 8.09 11.03
0.08 97.63 4.48 6.63
0.80 98.57 3.44 5.01
MVAL-D7 0.75 97.38 5.91 8.77
Table 4
Stability data of MVAL in processed QC samples for different stability activities in
different conditions (n¼6).
Conditions Nominal concentra-
tion (ng/mL)
Calculated con-
centration (ng/mL)
RE (%)
Short term stability 10 9.1770.45 8.33
(4 h, room temperature) 80 78.4071.63 2.79
800 774.2578.30 3.22
Pre-preparative stability 10 9.7170.64 2.88
(24 h, auto-sampler) 80 78.8370.22 1.38
800 790.5077.90 1.19
Freeze/thaw stability 10 9.4470.26 0.87
(3 cycles) 80 80.4072.63 1.02
800 784.6276.30 1.43
Long term stability for 10 8.1273.88 8.48
122 days (35°) 80 74.2078.43 6.88
800 768.91711.20 9.12
Table 5
The content of active ingredients in Xuezhikang calculated from lovastatin acid
standard curve.
Batch no. Xuezhikang
weight (g)
Nominal
concentration
(ng/mL)
Inhibition
rate (%)
Mean
back-calculated
concentration
(ng/mL)
Mean
content
(mg/g)
20140506 0.301 25 39.6 20.1 12.2
38.7
40.2
75 70.6 71.4
72.3
68.5
20140213 0.300 25 44.1 24.2 14.5
40.8
42.6
75 73.9 83.6
78.4
77.2
J. Wang et al. / Journal of Pharmaceutical Analysis 5 (2015) 383–388 3873.2.4. Extraction recovery
The extraction recovery of MVAL from the low, medium and
high QC samples ranged from 93.37% to 98.57% with a maximum
RSD of 11.03%. The extraction recovery of internal standards was
97.38% with a RSD of 8.77%. The results in Table 3 revealed that the
SPE approach employed in the present work provided re-
producible recoveries for MVAL and internal standard.
3.2.5. Stability
The stability studies of MVAL were performed at three QC
concentration levels (low, medium and high) in six replicates
(n¼6). The stability of MVAL was evaluated in storage at room
temperature for 4 h, as well as after three freeze/thaw cycles and
processed samples stored at the autosampler temperature (25 °C)
for 24 h. The long-term stability was also evaluated after the sto-
rage of QC samples at 35 °C for 122 days. The results of all sta-
bilities are given in Table 4.
3.3. Method application
The developed and validated method was used for the de-
termination of total lovastatin acid obtained from Xuezhikang
capsules. The prepared Xuezhikang sample solutions were added
into the HMG-CoA reductase reaction system in vitro. Lovastatinacid standard curve was established to evaluate the active in-
gredient. Table 5 shows that the contents of active ingredients in
Xuezhikang capsules which were back-calculated by inhibition
curves of lovastatin acid were tested to be 12.2 and 14.5 mg/g,
overtopping the sum of lovastatin and lovastatin acid in the same
batch of Xuezhikang detected directly by HPLC (12.1 and 12.5 mg/
g). The results indicated that there may be other ingredients which
also play the role in inhibiting HMG-CoA reductase in Xuezhikang.4. Conclusion
We developed and validated a method for the quantitation of
Xuezhikang with enzyme reaction in vitro, and acquired some
innovative points. Firstly, we optimized the HMG-CoA reductase
reaction which converts HMG-CoA to CoA and MVA using an LC–
MS/MS method for detection; secondly, we investigated the sta-
bility of the HMG-CoA reductase reaction system which was re-
producible; thirdly, the observed method was successfully used in
quantitation of the active ingredients of Xuezhikang capsules for
the ﬁrst time. The method is particularly valuable for the in-
vestigation of active ingredients, and can be applied to the quality
process control of Xuezhikang.
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